Overview

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Status:
RECRUITING
Trial end date:
2026-04-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics of enpatoran.
Phase:
PHASE1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Collaborator:
Merck KGaA, Darmstadt, Germany